Mediwound Ltd
MDWD18.030USD
-0.120-0.66%
終値 11/06, 16:00（ET）15分遅れの株価
196.09M時価総額
損失額直近12ヶ月PER
詳細情報 Mediwound Ltd 企業名
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltdの企業情報
企業コードMDWD
会社名Mediwound Ltd
上場日Mar 20, 2014
最高経営責任者「CEO」Mr. Ofer Gonen
従業員数111
証券種類Ordinary Share
決算期末Mar 20
本社所在地42 Hayarkon Street
都市YAVNE
証券取引所NASDAQ Global Market Consolidated
国Israel
郵便番号8122745
電話番号972779714100
ウェブサイトhttps://www.mediwound.com/
企業コードMDWD
上場日Mar 20, 2014
最高経営責任者「CEO」Mr. Ofer Gonen
Mediwound Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Dr. Robert J. Snyder
Dr. Robert J. Snyder
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
データなし
地域別USD
会社名
収益
比率
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
事業別
地域別
データなし
株主
更新時刻: 10 hours ago
更新時刻: 10 hours ago
株主統計
種類
株主統計
株主統計
比率
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
HOLD Alapkezelo Zrt
5.49%
Rosalind Advisors, Inc.
3.17%
他の
66.66%
株主統計
株主統計
比率
Clal Biotechnology Industries Ltd
11.55%
Investor AB
6.80%
Yelin Lapidot Provident Funds Management Ltd
6.32%
HOLD Alapkezelo Zrt
5.49%
Rosalind Advisors, Inc.
3.17%
他の
66.66%
種類
株主統計
比率
Investment Advisor
20.75%
Holding Company
11.55%
Investment Advisor/Hedge Fund
9.39%
Private Equity
6.80%
Hedge Fund
4.93%
Venture Capital
2.95%
Corporation
2.17%
Individual Investor
1.42%
Research Firm
0.37%
他の
39.66%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
134
5.86M
45.68%
+524.92K
2025Q2
127
6.70M
61.97%
-1.10M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
2023Q2
64
5.23M
72.67%
+954.42K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Clal Biotechnology Industries Ltd
1.48M
11.55%
--
--
Sep 30, 2025
Investor AB
872.09K
6.8%
--
--
Jun 30, 2025
Yelin Lapidot Provident Funds Management Ltd
816.74K
6.37%
-41.26K
-4.81%
Jun 30, 2025
HOLD Alapkezelo Zrt
703.43K
5.49%
+703.43K
--
Sep 22, 2025
Rosalind Advisors, Inc.
407.06K
3.17%
-99.83K
-19.69%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
388.27K
3.03%
-45.72K
-10.54%
Jun 30, 2025
Israel Biotech Fund
378.62K
2.95%
-172.63K
-31.32%
Mar 15, 2025
T. Rowe Price Associates, Inc.
369.08K
2.88%
+214.12K
+138.19%
Jun 30, 2025
Deep Insight Limited Partnership
278.18K
2.17%
-273.07K
-49.54%
Mar 15, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
ARK Israel Innovative Technology ETF
1.45%
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ARK Israel Innovative Technology ETF
比率1.45%
Invesco NASDAQ Future Gen 200 ETF
比率0.52%
iShares Micro-Cap ETF
比率0.03%
iShares Russell 2000 Growth ETF
比率0.01%
Global X Russell 2000 ETF
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Russell 2000 ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares UltraPro Russell2000
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
日付
種類
比率
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
